Can Elderly Patients with Peritoneal Metastasis Induced by Appendiceal or Colorectal Tumours Benefit from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)?

Purpose Cytoreductive surgery (CRS) added with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve the survival rate of certain patients with peritoneal metastasis (PM). However, the perioperative safety and long-term survival of this intricate and possibly life-threatening procedure in elderly patients (≥65 years) remain controversial. Methods Patients with PM due to appendiceal or colorectal tumours who underwent CRS/HIPEC were evaluated systematically at the National Cancer Center of China and the Huanxing Cancer Hospital between June 2017 and June 2019. The recruited subjects were retrospectively categorized into elderly (age ≥65) and non-elderly (age<65) groups according to their age. Clinical and pathological features, postoperative outcomes, and prognoses were gathered and analysed. Results Both groups had similar overall morbidity (56.0% vs 38.7%, P=0.130) and grade 3/4 morbidity (28.0% vs 20.0%, P=0.403) after CRS/HIPEC. However, more patients in the elderly group suffered from ileus postoperatively (16.0% vs 2.6%, P=0.033). After a follow-up period of a median of 20 months, it was concluded that elderly patients had significantly worse 3-year overall survival (OS) than non-elderly patients (16.3% vs 51.4%, P=0.001). Independent prognostic factors were identified to be a high peritoneal carcinomatosis index (PCI) score (HR, 1.10, 95% CI, 1.04–1.16; P=0.001) and age ≥65 (HR, 2.42, 95% CI, 1.32–4.45; P=0.004) were independent prognostic factors through cox regression analysis. Conclusion CRS and HIPEC are related with an elevated prevalence of postoperative ileus but not with the overall morbidity or the grade 3/4 morbidity in elderly patients. However, since worse survival outcomes were observed more commonly in elderly patients compared to younger patients from CRS+HIPEC, this complex and potentially life-threatening procedure should be considered carefully in patients aged ≥65 years.

[1]  R. Ramsay,et al.  Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis , 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[2]  K. Soo,et al.  High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy , 2020, International Journal of Clinical Oncology.

[3]  J. Tuynman,et al.  Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. , 2019, The lancet. Gastroenterology & hepatology.

[4]  I. Syk,et al.  Postoperative complications following colonic resection for cancer are associated with impaired long‐term survival , 2019, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[5]  D. Morris,et al.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  K. Soo,et al.  Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) , 2018 .

[7]  N. Aaronson,et al.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer , 2018, The New England journal of medicine.

[8]  G. Cai,et al.  Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature , 2016, Gastroenterology research and practice.

[9]  P. Parrilla,et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients. A systematic literature review. , 2016, Surgical oncology.

[10]  A. Königsrainer,et al.  Overall morbidity but not mortality is increased in elderly patients following cytoreductive surgery and HIPEC , 2015, Langenbeck's Archives of Surgery.

[11]  R. Loffeld,et al.  Thirty days post-operative mortality after surgery for colorectal cancer: a descriptive study. , 2015, Journal of gastrointestinal oncology.

[12]  V. Lemmens,et al.  Patterns of metachronous metastases after curative treatment of colorectal cancer. , 2014, Cancer epidemiology.

[13]  Sabha Rasool,et al.  A comparative overview of general risk factors associated with the incidence of colorectal cancer , 2013, Tumor Biology.

[14]  Melissa C C Teo,et al.  Peritoneal-based malignancies and their treatment. , 2010, Annals of the Academy of Medicine, Singapore.

[15]  T. Chua,et al.  Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality , 2009, Annals of surgery.

[16]  R. Beart,et al.  Impact of the Aging Population on the Demand for Colorectal Procedures , 2009, Diseases of the colon and rectum.

[17]  M. Ducreux,et al.  Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy , 2001, Cancer.

[18]  P. Sugarbaker.  Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[19]  B. Glimelius,et al.  Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. , 2016, European journal of cancer.

[20]  M. P. Tristan D. Yan BSc,et al.  Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis , 2008, Annals of Surgical Oncology.

[21]  Cancer Therapy Evaluation Program.  Common Terminology Criteria for Adverse Events v3.0 (CTCAE) , 2003 .

[22]  P. Sugarbaker,et al.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. , 1996, Cancer treatment and research.